Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Effectiveness of Ampicillin-Sulbactam and Ceftriaxone for Treating Community-Acquired Pneumonia in Elderly Patients: Insights from a Target Trial Emulation Analysis

  • By

  • Shungo Yamamoto

  • Akihiro Shiroshita

  • Yuki Kataoka

  • Hidehiro Someko

  • March 5, 2025

Share

  • 1

    Ampicillin-sulbactam was associated with higher in-hospital mortality compared to ceftriaxone in elderly patients with community-acquired pneumonia.

  • 2

    The study analyzed data from 26,633 older patients hospitalized for community-acquired pneumonia between May 2010 and June 2023.

  • 3

    The incidence of Clostridioides difficile infection was numerically higher in the ampicillin-sulbactam group than in the ceftriaxone group.

  • 4

    This research utilized a target trial emulation framework to compare the effectiveness of the two antibiotic treatments.

  • 5

    Current guidelines do not mandate routine anaerobic coverage for community-acquired pneumonia, reflecting changes in bacterial prevalence.

Original Source(s)

Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study

  • by Shungo Yamamoto, Akihiro Shiroshita, Yuki Kataoka, Hidehiro Someko

  • March 5, 2025

Related Content

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Refining Vancomycin Use in Early CDI

A modified dosing approach could reshape recurrence prevention strategies.

Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3